We identify the underlying cause of your discomfortwhether it stems from arthritis, repetitive stress, sports injury, or chronic inflammation
These drug supply issues are a great opportunity to have patient management reviews, emphasise principles around healthy lifestyle, and review therapies including prescribing options or even de-prescribing if possible. Alternative treatment options suggested by the RACGP include: Liraglutide, which is administered once daily and has evidence of cardiovascular benefit, but is not subsidised by PBS SGLT-2 inhibitors, especially in those who also have cardiovascular disease, multiple cardiovascular risk factors and/or kidney disease DPP-4 inhibitors, which may be useful in those who do not have cardiovascular disease, multiple cardiovascular risk factors or kidney disease, and are unable to achieve optimal blood glucose levels Sulphonylureas or insulin (initiation or titrated doses), but these may lead to risks for hypoglycaemia and weight gain The twice daily exenatide (Byetta) is not recommended as a potential substitute, as it is being discontinued and will no longer be available once existing stock runs out, which is predicted to occur next month
These can include nausea, vomiting, diarrhea, constipation, and bloating
Ultimately, initiating GLP-1 therapy before full thyroid optimization is a clinical judgment call that should weigh the urgency of metabolic control against the risk of confusing the symptoms or destabilizing thyroid function
Common side effects include gastrointestinal issues like diarrhea, as well as headaches
